ID: ALA4215021

Max Phase: Preclinical

Molecular Formula: C33H39NO3

Molecular Weight: 497.68

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC1(C)CCC(C)(C)c2cc(-c3cc(-c4ccc(C(=O)O)cc4)ccc3OCCCNC3CC3)ccc21

Standard InChI:  InChI=1S/C33H39NO3/c1-32(2)16-17-33(3,4)29-21-25(10-14-28(29)32)27-20-24(22-6-8-23(9-7-22)31(35)36)11-15-30(27)37-19-5-18-34-26-12-13-26/h6-11,14-15,20-21,26,34H,5,12-13,16-19H2,1-4H3,(H,35,36)

Standard InChI Key:  OGLIECHDQHKIDU-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 497.68

Molecular Weight (Monoisotopic): 497.2930

AlogP: 7.59

#Rotatable Bonds: 9

Polar Surface Area: 58.56

Molecular Species: ZWITTERION

HBA: 3

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 4.08

CX Basic pKa: 9.86

CX LogP: 5.08

CX LogD: 5.08

Aromatic Rings: 3

Heavy Atoms: 37

QED Weighted: 0.30

Np Likeness Score: 0.04

References

1. Thoreau E, Arlabosse JM, Bouix-Peter C, Chambon S, Chantalat L, Daver S, Dumais L, Duvert G, Feret A, Ouvry G, Pascau J, Raffin C, Rodeville N, Soulet C, Tabet S, Talano S, Portal T..  (2018)  Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.,  28  (10): [PMID:29706423] [10.1016/j.bmcl.2018.04.036]

Source

Source(1):

• Scientific Literature